ABSTRACT
Our objective was to compare the efficacy and safety of rectal cation-exchange resin (Kayexalate) versus salbutamol infusion for the treatment of nonoliguric hyperkalemia (NOHK) in preterm infants. Data of all neonates born with NOHK during the study period of 6 years and 8 months were recorded. Diagnostic criteria of NOHK included serum potassium (SK) concentration ≥ 7 mmol/L during the first 72 hours of life with urine output ≥ 1 mL/kg/hour. This before-after study was divided according to the date of admission; the first 15 patients were treated with Kayexalate enema 1 g/kg every 4 hours, and the remaining 30 patients were treated with intravenous salbutamol infusion as 4 μg/kg every 4 hours. Treatment discontinued when SK became < 6 mmol/L. SK was measured every 4 hours. Daily urine was collected. Fluid intake and output, serum electrolytes, urea, creatinine, and glucose concentrations were obtained in all infants every 12 hours. All infants were observed with a cardiorespiratory monitor and oxygen saturation and blood pressure measurements. Perinatal characteristics in both groups were comparable. Mean gestational age was 26 and 28 weeks for salbutamol and Kayexalate, respectively. The peak of SK ranged between 7 and 9.3 mmol/L in the Kayexalate group and between 7 and 8.7 mmol/L in the salbutamol group (p = 0.64). At 12 hours of treatment, SK became normal in only 4 patients (26%) in the Kayexalate group compared with 18 patients (60%) in the salbutamol group (p = 0.003). The number of doses of Kayexalate administration was significantly higher than the doses of salbutamol (p = 0.003). No significant side effects were detected in the salbutamol-treated infants. In contrast, there were two cases of severe ventricular tachycardia and one case of intestinal obstruction in the cation-exchange resin group. We concluded that salbutamol infusion is more effective with faster action and safer than cation-exchange resin (Kayexalate) for the treatment of NOHK in preterm infants.
KEYWORDS
Nonoliguric hyperkalemia - Kayexalate - Salbutamol - preterm
REFERENCES
-
1
Apitz C, Wirbelauer J.
Circulatory failure due to severe cardiac arrhythmia as a result of hyperkalemia in a very low birth weight infants.
Klin Padiatr.
2006;
218
16-19
-
2
Brion L P, Schwartz G J, Campbell D, Fleichman A R.
Early hyperkalemia in very low birth weight infants in the absence of oliguria.
Arch Dis Child.
1989;
64
270-272
-
3
Mildenberger E, Versmold H T.
Pathogenesis and therapy of non-oliguric hyperkalemia of the premature infant.
Eur J Pediatr.
2002;
161
415-422
-
4
Stefano J L, Norman M E, Morales M C.
Decreased erythrocyte Na + , K( + )-ATPase activity associated with cellular potassium loss in extremely low birth weight infants with nonoliguric hyperkalemia.
J Pediatr.
1993;
122
276-284
-
5
Malone T A.
Glucose and insulin versus cation-exchange resin for the treatment of hyperkalemia in VLBW infants.
J Pediatr.
1991;
118
121-123
-
6
Singh B S, Sadiq H F, Noguchi A, Keenan W J.
Efficacy of albuterol inhalation in treatment of hyperkalemia in premature neonates.
J Pediatr.
2002;
141
16-20
-
7
Murdoch I A, Dos Anjos R, Haycock G B.
Treatment of hyperkalemia with intravenous salbutamol.
Arch Dis Child.
1991;
66
527-528
-
8
McClure R J, Prasad V K, Brocklebonk J T.
Treatment of hyperkalemia using intravenous and nebulised salbutamol.
Arch Dis Child.
1994;
70
126-128
-
9
Su B H, Peng C T, Tsai C H. Hu Ps .
Glucose and insulin infusion versus Kayexalate for the early treatment of non-oliguric hyperkalemia in VLBW infants.
Acta Paediatr Taiwan.
1999;
40
314-318
-
10
Lorenz J M, Kleinman L I, Markarian K.
Potassium metabolism in extremely low birth weight infants in the first week of life.
J Pediatr.
1997;
131
81-86
-
11
Whyte K F, Addis G J, Whithesmith R.
The mechanism of salbutamol-induced hypokalemia.
Br J Clin Pharmacol.
1987;
23
65-71
-
12
Vemgal P, Ohlsson A.
Interventions for non-oliguric hyperkalaemia in preterm neonates.
Cochrane Database Syst Rev.
2007;
1
CD005257
-
13
Omar S A, DeCristofaro J D, Agarwal B I, La Gamma E F.
Effect of prenatal steroids on potassium balance in ELBW neonates.
Pediatrics.
2000;
106
561-567
-
14
Kemper M J, Harps E, Hellwege H H, Müller-Wiefel D E.
Effective treatment of acute hyperkalemia in childhood by short term infusion of salbutamol.
Eur J Pediatr.
1996;
155
495-497
-
15
Mandelberg A, Krupnik Z, Houri S, Smetana S.
Salbutamol metered-dose inhaler with spacer for hyperkalemia. How fast? How safe?.
Chest.
1999;
115
617-622
-
16
Bennet L N, Myers T F, Lambert G H.
Cecal perforation associated with sodium polystyrene sulfonate-sorbitol enemas in a 650 gram infant with hyperkalemia.
Am J Perinatol.
1996;
13
167-170
-
17
Rugolotto S, Gruber M, Solano P D, Chini L, Pecori S.
Necrotizing enterocolitis in an 850 gram infant receiving sorbitol-free sodium polystyrene sulfonate (Kayexalate): clinical and histopathologic findings.
J Perinatal.
2007;
27(4)
247-249
-
18
Filippi L, Cecchi A, Dani C, Bertini G, Pezzati M, Rubaltelli F F.
Hypernatremia induced by sodium polystyrene sulphonate (Kayexalate) in two extremely low birth weight newborns.
Paediatr Anaesth.
2004;
14(3)
271-275
-
19
Greenough A, Emery E F, Brooker R, Gamsu H R.
Salbutamol infusion to treat neonatal hyperkalemia.
J Prenatal Med.
1992;
20
437-441
Dr. Hakam YaseenM.D.
Senior Consultant Neonatologist, Neonatal Units, Al Qassimi Hospital
PO Box 25624, Sharjah, United Arab Emirates
